MetaVia's DA-1726 Cuts Liver Fat 68% and Weight 13.5% in Phase 1 Part 3B Interim
MTVA sits 37% above its 52-week low of $0.966 on elevated volume (1.8× avg).
Summary
MetaVia reported interim Phase 1 Part 3B data showing DA-1726 cut liver fat 68% and body weight 13.5% versus placebo at 16 weeks, with no new GI adverse events after Week 9. The result supports a planned 48-week Phase 2 in MetALD/ALD starting 2H 2027, but the company needs financing to fund it.
Key Events · Product Development and Regulatory · MTVA
-
68% Placebo-Adjusted Liver Fat Cut
At Day 109 (~16 weeks), DA-1726 produced a 68% placebo-adjusted liver fat reduction (MRI-PDFF, GMR 0.32, p<0.001) in the MRI substudy of 12 active and 4 placebo participants; 10 of 12 (83%) hit at least a 30% relative reduction versus none on placebo.
-
13.5% Weight Loss, HbA1c Down
Body weight fell 12.19 kg (-11.9%) from a 98.6 kg baseline, a 13.5% placebo-adjusted difference (n=15 vs 4, p<0.001), while HbA1c dropped 0.44 pp to 5.33% (-0.24 pp placebo-adjusted, p=0.006) in non-diabetic participants.
-
Cleaner Tolerability After Week 9
No new GI adverse events were reported after Week 9 (Day 63) through Day 109 and no participant discontinued for a GI event; one serious adverse event of severe vomiting was possibly related and the participant recovered.
-
Phase 2 MetALD/ALD Targeted 2H 2027
MetaVia plans a 48-week, non-biopsy Phase 2 in up to 150 MetALD/ALD subjects starting 2H 2027, with full Part 3A and Part 3B data expected in Q1 2027.
Analysis · MTVA · Life Sciences
This is the first hard efficacy readout on DA-1726, and it is strong on all three axes the company needs: 68% placebo-adjusted liver fat reduction, 13.5% placebo-adjusted weight loss and a 0.24 pp placebo-adjusted HbA1c drop, all at 16 weeks with no new GI adverse events after Week 9 and no GI-driven discontinuations. For a company with a $12.6M cash balance as of June 30, 2026 and a runway only into 1Q 2027, the data are the main lever for raising the capital the 2027 programs require — the presentation itself says those programs are contingent on additional financing. The caveats are real: tiny arms (n=15 active vs 4 placebo; MRI substudy n=12 vs 4), interim rather than final data, and the liver-disease Phase 2 does not start until 2H 2027. Full Part 3A/3B topline in Q1 2027 is the next hard checkpoint.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MTVA was trading at $1.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.8M. The 52-week trading range was $0.97 to $14.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.